Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Tax Provisions (2021 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Tax Provisions for 4 consecutive years, with -$3000.0 as the latest value for Q4 2025.

  • Quarterly Tax Provisions rose 94.44% to -$3000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $525000.0 through Dec 2025, up 37.8% year-over-year, with the annual reading at $497000.0 for FY2025, 43.64% up from the prior year.
  • Tax Provisions for Q4 2025 was -$3000.0 at Rhythm Pharmaceuticals, down from $111000.0 in the prior quarter.
  • The five-year high for Tax Provisions was $22.0 million in Q1 2021, with the low at -$9.0 million in Q3 2021.
  • Average Tax Provisions over 4 years is $727615.4, with a median of $111000.0 recorded in 2025.
  • The sharpest move saw Tax Provisions plummeted 193.48% in 2024, then skyrocketed 132.27% in 2025.
  • Over 4 years, Tax Provisions stood at -$9.0 million in 2021, then surged by 102.18% to $196000.0 in 2023, then crashed by 127.55% to -$54000.0 in 2024, then skyrocketed by 94.44% to -$3000.0 in 2025.
  • According to Business Quant data, Tax Provisions over the past three periods came in at -$3000.0, $111000.0, and $337000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.